Published in Biofactors on January 01, 2008
Functional genomics of allergen gene families in fruits. Nutrients (2009) 0.75
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature (2002) 9.62
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J Virol (2002) 7.82
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol (2002) 6.11
Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med (2005) 5.68
Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol (2004) 5.29
Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity (2005) 4.26
Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci U S A (2005) 2.50
Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis (2004) 2.47
The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol (2004) 2.02
Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J Virol (2007) 1.81
Influenza A mutant viruses with altered NS1 protein function provoke caspase-1 activation in primary human macrophages, resulting in fast apoptosis and release of high levels of interleukins 1beta and 18. J Gen Virol (2005) 1.78
Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J Virol (2005) 1.68
In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol (2007) 1.56
Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS (2003) 1.55
Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. Biochemistry (2007) 1.46
Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12. J Virol (2003) 1.45
Rescue of influenza virus expressing GFP from the NS1 reading frame. Virology (2004) 1.45
Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS (2007) 1.44
Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes. J Virol (2004) 1.44
Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. AIDS (2006) 1.43
Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. J Virol (2004) 1.40
hTERT alone immortalizes epithelial cells of renal proximal tubules without changing their functional characteristics. Am J Physiol Renal Physiol (2008) 1.40
Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies. AIDS Res Hum Retroviruses (2006) 1.30
Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). Antimicrob Agents Chemother (2006) 1.27
Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody. AIDS Res Hum Retroviruses (2004) 1.24
Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope. J Virol (2009) 1.21
Strategies for antiviral resistance in transgenic plants. Mol Plant Pathol (2008) 1.20
In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. J Virol (2007) 1.20
Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation. AIDS (2002) 1.17
The carbohydrate epitope of the neutralizing anti-HIV-1 antibody 2G12. Adv Exp Med Biol (2003) 1.15
Interaction of U-box E3 ligase SNEV with PSMB4, the beta7 subunit of the 20 S proteasome. Biochem J (2005) 1.14
Electron microscopic and immunochemical analysis of the broadly neutralizing HIV-1-specific, anti-carbohydrate antibody, 2G12. Mol Immunol (2004) 1.11
Contributions of DNA interstrand cross-links to aging of cells and organisms. Nucleic Acids Res (2007) 1.09
SNEV is an evolutionarily conserved splicing factor whose oligomerization is necessary for spliceosome assembly. Nucleic Acids Res (2005) 1.08
HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies. AIDS (2005) 1.08
Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol (2005) 1.08
Comparison of early passage, senescent and hTERT immortalized endothelial cells. Exp Cell Res (2005) 1.07
Process parameter shifting: Part I. Effect of DOT, pH, and temperature on the performance of Epo-Fc expressing CHO cells cultivated in controlled batch bioreactors. Biotechnol Bioeng (2006) 1.07
SNEV overexpression extends the life span of human endothelial cells. Exp Cell Res (2006) 1.06
Combined 2D electrophoretic approaches for the study of white lupin mature seed storage proteome. Phytochemistry (2007) 1.04
Effect of increased expression of protein disulfide isomerase and heavy chain binding protein on antibody secretion in a recombinant CHO cell line. Biotechnol Prog (2005) 1.03
Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment. J Virol (2005) 1.02
Live cold-adapted influenza A vaccine produced in Vero cell line. Virus Res (2004) 1.01
Structural analysis and in vivo administration of an anti-idiotypic antibody against mAb 2F5. Mol Immunol (2007) 0.98
Specific effects of synthetic oligopeptides on cultured animal cells. Biotechnol Prog (2002) 0.97
Early embryonic lethality of mice lacking the essential protein SNEV. Mol Cell Biol (2007) 0.97
Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts. J Virol (2006) 0.97
MicroRNAs as targets for engineering of CHO cell factories. Trends Biotechnol (2008) 0.97
Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques. Virology (2006) 0.97
Functional analysis of the broadly neutralizing human anti-HIV-1 antibody 2F5 produced in transgenic BY-2 suspension cultures. FASEB J (2007) 0.97
Influenza virus NS vectors expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge. Clin Vaccine Immunol (2006) 0.95
Distinct host range of influenza H3N2 virus isolates in Vero and MDCK cells is determined by cell specific glycosylation pattern. Virology (2003) 0.95
Partial humanization and characterization of an anti-idiotypic antibody against monoclonal antibody 2F5, a potential HIV vaccine? AIDS Res Hum Retroviruses (2007) 0.95
Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B. AIDS Res Hum Retroviruses (2003) 0.93
Bioactive compounds in berries relevant to human health. Nutr Rev (2009) 0.93
Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine. J Infect Dis (2003) 0.93
Process parameter shifting: Part II. Biphasic cultivation-A tool for enhancing the volumetric productivity of batch processes using Epo-Fc expressing CHO cells. Biotechnol Bioeng (2006) 0.93
Anti-idiotypic antibody Ab2/3H6 mimics the epitope of the neutralizing anti-HIV-1 monoclonal antibody 2F5. AIDS (2002) 0.93
Aging and the ubiquitinome: traditional and non-traditional functions of ubiquitin in aging cells and tissues. Exp Gerontol (2006) 0.93
Characterization of a trimeric MPER containing HIV-1 gp41 antigen. Virology (2009) 0.92
Telomerase immortalized human amnion- and adipose-derived mesenchymal stem cells: maintenance of differentiation and immunomodulatory characteristics. Tissue Eng Part A (2009) 0.91
Enhancement of monoclonal antibody production by lysine-containing peptides. Biotechnol Prog (2003) 0.90
High level expression of a promising anti-idiotypic antibody fragment vaccine against HIV-1 in Pichia pastoris. J Biotechnol (2007) 0.90
MdAP, a novel protein in apple, is associated with the major allergen Mal d 1. Gene (2003) 0.89
The HIV-neutralizing monoclonal antibody 4E10 recognizes N-terminal sequences on the native antigen. J Immunol (2006) 0.89
Effects of antibody on viral kinetics in simian/human immunodeficiency virus infection: implications for vaccination. J Virol (2004) 0.89
Serum-free transfection of CHO cells with chemically defined transfection systems and investigation of their potential for transient and stable transfection. Cytotechnology (2009) 0.88
The absence of effect of gene copy number and mRNA level on the amount of mAb secretion from mammalian cells. Appl Microbiol Biotechnol (2008) 0.87
Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked. J Virol (2008) 0.86
Transgene silencing in grapevines transformed with GFLV resistance genes: analysis of variable expression of transgene, siRNAs production and cytosine methylation. Transgenic Res (2009) 0.86
GMP production of liposomes--a new industrial approach. J Liposome Res (2006) 0.86
Molecular characterization of grapevine plants transformed with GFLV resistance genes: I. Plant Cell Rep (2005) 0.86
Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6. J Mol Biol (2008) 0.86
Characterisation of recombinant CHO cell lines by investigation of protein productivities and genetic parameters. J Biotechnol (2006) 0.85
Proline is not uniquely capable of providing the pivot point for domain swapping in 2G12, a broadly neutralizing antibody against HIV-1. J Biol Chem (2009) 0.85
Protein-free transfection of CHO host cells with an IgG-fusion protein: selection and characterization of stable high producers and comparison to conventionally transfected clones. Biotechnol Bioeng (2007) 0.85
Effect of postharvest storage on the expression of the apple allergen Mal d 1. J Agric Food Chem (2006) 0.84
Jatropha curcas, a biofuel crop: functional genomics for understanding metabolic pathways and genetic improvement. Biotechnol J (2013) 0.84
Low telomerase activity: possible role in the progression of human medullary thyroid carcinoma. Eur J Cancer (2008) 0.84
Bacterial expression and refolding of human trypsinogen. J Biotechnol (2004) 0.84
Genome size, karyotyping and FISH physical mapping of 45S and 5S genes in two cherry rootstocks: Prunus subhirtella and Prunus incisa xserrula. J Biotechnol (2010) 0.84
Sample preparation and 2-DE procedure for protein expression profiling of black microcolonial fungi. Fungal Biol (2011) 0.83
Optimization of recombinant protein expression level in Escherichia coli by flow cytometry and cell sorting. Biotechnol Bioeng (2002) 0.83
Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection. J Antimicrob Chemother (2003) 0.83
Molecular characterization of grapevine plants transformed with GFLV resistance genes: II. Plant Cell Rep (2006) 0.83
Blom7alpha is a novel heterogeneous nuclear ribonucleoprotein K homology domain protein involved in pre-mRNA splicing that interacts with SNEVPrp19-Pso4. J Biol Chem (2009) 0.82
Altering the surface properties of baculovirus Autographa californica NPV by insertional mutagenesis of the envelope protein gp64. Eur J Biochem (2002) 0.82
Stress regulated expression of the GUS-marker gene (uidA) under the control of plant calmodulin and viral 35S promoters in a model fruit tree rootstock: Prunus incisa x serrula. J Biotechnol (2008) 0.81
Confocal microscopy of giant vesicles supports the absence of HIV-1 neutralizing 2F5 antibody reactivity to plasma membrane phospholipids. FEBS Lett (2010) 0.81
Nuclear flow FISH: isolation of cell nuclei improves the determination of telomere lengths. Exp Gerontol (2005) 0.81
Fruit cross-reactive allergens: a theme of uprising interest for consumers' health. Biofactors (2005) 0.81
Long-term stability of marker gene expression in Prunus subhirtella: a model fruit tree species. J Biotechnol (2006) 0.80
Mapping of Malus domestica allergens by 2-D electrophoresis and IgE-reactivity. Electrophoresis (2007) 0.80
One- and two-dimensional electrophoretic identification of IgE-binding polypeptides of Lupinus albus and other legume seeds. J Agric Food Chem (2005) 0.80